A Phase 3 interventional study of 18F-sodium fluoride in Bone Cancer, Articular Disease and Infectious Disease, sponsored by Centre de recherche du Centre hospitalier universitaire de Sherbrooke. Recruiting at 2 sites in Canada. Per ClinicalTrials.gov, last updated 2024-02-07.
Sponsored by Centre de recherche du Centre hospitalier universitaire de Sherbrooke · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Bone Neoplasms with a site in Canada — 2 open to participants now, 4 under way, 1 of them phase 3. Bone Neoplasms · Canada.
Among the 18 studies in Bone Neoplasms with a site in Canada, this one has the largest planned enrollment of the 17 interventional ones that give a count, is one of 3 that started in 2008, is one of 5 in phase 3, and was the 17th registered.
259 studies on the registry are indexed under Bone Neoplasms; 70 are open to participants now.
Browse Bone Neoplasms studies →2 of the 18 studies in Bone Neoplasms with a site in Canada are open now. Recruiting first, the newest first:
University Health Network, Toronto · Sites in Canada
Ages 0–64
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 54 Bone Neoplasms studies recruiting now, 35 (65%) set no upper age limit and 13 (24%) stop at 75 or younger; 25 take children under 18; 4 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,500 is above the median of 44 across 163 interventional studies indexed under Bone Neoplasms.
Median enrollment 128 across the 17 interventional studies, 245 across the 1 observational. Of the 14 that completed or were terminated, 8 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 18 have an industry lead sponsor. The 10 most frequent:
Centre de recherche du Centre hospitalier universitaire de Sherbrooke is the lead sponsor of 29 studies on the registry; 10 are open to participants now.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke has 1 study filed under Bone Neoplasms — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Bone Neoplasms with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
18F-sodium fluoride (18F-NaF) was already investigated numerous times in the last 40 years as a PET alternative to standard 99m-technetium-derived bone scintigraphy. However, lack of universal tracer availability and higher costs contributed to the failure of 18F-NaF to systematically supplant bone scintigraphy as a standard of care.
Recently, an isotope shortage crisis occurred and evidenced the need to have non-reactor-derived alternatives for many nuclear medicine procedures, including bone scintigraphy. Since 18F-NaF is cyclotron-produced, it could become a necessary alternative to bone scintigraphy in case of another worldwide isotope shortage.
The study aims to evaluate the safety profile of 18F-NaF injection. Moreover, a patient registry will be compiled in order to perform sub-studies on 18F-NaF diagnostic performance on diverse bone and articular diseases.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligibility for 18F-NaF PET scans is the same than for bone scintigraphy routinely prescribed in the clinic.
Diagnostic Test: 18F-sodium fluoride
Intravenous injection of 4 MBq/kg for pediatric patients, or 5 MBq/kg for adult patients (maximum of 555 MBq), followed by a 45 minutes waiting time. Patients is then placed in supine position in a PET/CT scanner for a duration of no more than 30 minutes.
Also known as: 18F-NaF
Safety profile of 18F-NaF
A registry monitoring eventual adverse effects for this radiopharmaceutical agent will be compiled. Usual procedures will be applied to divulgate any serious adverse effects.
Time frame: 17 years
Efficacy profile of 18F-NaF compared to 99mTc-biphosphonate bone scintigraphy
Using the patient registry, and in the eventual sub-studies to come, the diagnostic performance of 18F-NaF-PET will be compared to similar available imaging tests, most notably 99mTc-biphosphonate bone scintigraphy.
Time frame: 17 years
Correlate 18F-NaF PET images with pathology reports
Pathology data from the diverse conditions eligible for the 18F-NaF PET scan will be also monitored when available. Prognostic value from the imaging data will be compared with those obtained from the pathology.
Time frame: 17 years
Plan to share: No
No publications or documents are linked to this record.
Started Jan 2008 (actual). Primary completion is estimated for Dec 2025, 215 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre de recherche du Centre hospitalier universitaire de Sherbrooke